Your browser doesn't support javascript.
loading
Human calprotectin, a potent anticancer with minimal side effect
Iranian Journal of Cancer Prevention. 2009; 2 (4): 183-188
em Inglês | IMEMR | ID: emr-111913
ABSTRACT
Chemotherapy by using agents such as etoposide is a common way for inhibition of tumors. This treatment is accompanied by many undesirable side effects. Calprotectin is an abundant protein in the neutrophil cytosol, it has growth-inhibitory and apoptosis-inducing activities against various cell types such as tumor cells. In this study to introduce calprotectin as a suitable substitute anticancer, its growth inhibitory effect on human gastric adenocarcinoma cell line [AGS] and human foreskin fibroblast cells [HFFF] is compared to etoposide effect on these two cell lines. Calprotectin was purified from human neutrophil by chromatography methods. AGS and HFFF cell lines were used. These cells were maintained in RPMI 1640 medium supplemented with 10% FCS in a humidified incubator [37 §C and 5% CO2]. AGS cells [10000 cells per well] were exposed to the different concentrations of calprotectin and etoposide for 24 and 48 h. MTT assay was used for evaluation of cytotoxicity. Results indicate that calprotectin has more potent anticancer activity in comparison to the etoposide but it has nearly similar inhibitory effect on the proliferation of fibroblast cells. Since calprotectin affect about 20 times more than etoposide on cancer cells, without any additional side effect, it can be concluded that it is a suitable candidate to be studied as anticancer drug
Assuntos
Buscar no Google
Índice: IMEMR (Mediterrâneo Oriental) Assunto principal: Complexo Antígeno L1 Leucocitário / Etoposídeo / Antineoplásicos Limite: Humanos Idioma: Inglês Revista: Iran. J. Cancer Prevention Ano de publicação: 2009

Similares

MEDLINE

...
LILACS

LIS

Buscar no Google
Índice: IMEMR (Mediterrâneo Oriental) Assunto principal: Complexo Antígeno L1 Leucocitário / Etoposídeo / Antineoplásicos Limite: Humanos Idioma: Inglês Revista: Iran. J. Cancer Prevention Ano de publicação: 2009